Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press33610.17650/1994-4098-2008-0-1-41-44PHARMACOTHERAPYГИНЕКОЛОГИЯ. ФАРМАКОТЕРАПИЯСОВРЕМЕННЫЕ АСПЕКТЫ ПРИМЕНЕНИЯ ТАКСОТЕРА® ПРИ ДИССЕМИНИРОВАННОМ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫЮрашкоК. В.Russian FederationГорбуноваВ. А.Russian FederationСамойленкоВ. М.Russian FederationРОНЦ им. Н.Н. Блохина РАМН, ЦКВГ ФСБ РФ, Москва150220081414415092014150920142008https://ojrs.abvpress.ru/ojrs/article/view/336
СОВРЕМЕННЫЕ АСПЕКТЫ ПРИМЕНЕНИЯ ТАКСОТЕРА® ПРИ ДИССЕМИНИРОВАННОМ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ
1. Fisher B., Osborn K., Margolese R. et al. Neoplasms of the breast. Cancer medi- cine. 3-d edition. Ed. By J. Holland et al.; 1993. p. 1706—74.Fisher B., Osborn K., Margolese R. et al. Neoplasms of the breast. Cancer medi- cine. 3-d edition. Ed. By J. Holland et al.; 1993. p. 1706—74.2. Jones S.E., Erban J., Overmoyer B. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542—51.Jones S.E., Erban J., Overmoyer B. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542—51.3. Harvey V., Mouridsen H., Semiglazov V. et. al. Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. J Clin Oncol 2006;24(31):4963—70.Harvey V., Mouridsen H., Semiglazov V. et. al. Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. J Clin Oncol 2006;24(31):4963—70.4. Chan S., Friedricks K., Noel D. et al. Prostective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. TAX 303. J Clin Oncol 1999;17:2341—54.Chan S., Friedricks K., Noel D. et al. Prostective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. TAX 303. J Clin Oncol 1999;17:2341—54.5. Nabholtz J.M., Senn H.J., Bezwoda W.R. et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblas- tine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413—24.Nabholtz J.M., Senn H.J., Bezwoda W.R. et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblas- tine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999;17:1413—24.6. O'Shaughnessy J., Miles D., Vukelja S. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812—23.O'Shaughnessy J., Miles D., Vukelja S. et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812—23.7. Nabholtz J.M., Falkson C., Campos D. et al. Docetaxel and doxorubicin com- pared with doxorubicin and cyclophos- phamide as first-line chemotherapy for metastatic breast cancer. Results of a ran-Nabholtz J.M., Falkson C., Campos D. et al. Docetaxel and doxorubicin com- pared with doxorubicin and cyclophos- phamide as first-line chemotherapy for metastatic breast cancer. Results of a ran-domized, multicenter, phase III trial. J Clin Oncol 2003;21:968—75.8. Bontenbal M., Creemers G.J., Braun H.J. et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer. Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005;23:7081—8.Bontenbal M., Creemers G.J., Braun H.J. et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer. Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005;23:7081—8.9. Bonneterre J., Dieras V., Tubiana-Hulin M. et al. Phase II multi- centre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004;91:1466—71.Bonneterre J., Dieras V., Tubiana-Hulin M. et al. Phase II multi- centre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004;91:1466—71.